✦ LIBER ✦

First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours

✍ Scribed by Yasuhito Fujisaka, Yusuke Onozawa, Takayasu Kurata, Hirofumi Yasui, Isao Goto, Kentaro Yamazaki, Nozomu Machida, Junichiro Watanabe, Hitoshi Shimada, Xiaojin Shi, Narikazu Boku

Book ID: 118299101
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 188 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-012-9809-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1252 POSTER First Report of the Safety,

1252 POSTER First Report of the Safety, Tolerability, and Pharmacokinetics of Saracatinib (AZD0530) in Japanese Patients With Advanced Solid Tumours

✍ Y. Onozawa; Y. Fujisaka; H. Yasui; T. Kurata; K. Yamazaki; I. Goto; N. Machida; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Phase I Study to Assess the Safety, Tole

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

✍ Taito Esaki; Takashi Seto; Hiroshi Ariyama; Shuji Arita; Chinatsu Fujimoto; Koic 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 591 KB

A phase II trial of the Src kinase inhib

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium

✍ Helen J. Mackay, Heather J. Au, Elaine McWhirter, Thierry Alcindor, Andrea Jarvi 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 116 KB

1236 POSTER Phase I Study to Assess the

1236 POSTER Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of the Multikinase Inhibitor Regorafenib (BAY 73-4506) in Japanese Patients With Advanced Solid Tumours

✍ J. Furuse; Y. Sasaki; T. Okusaka; M. Ikeda; F. Nagashima; Y. Sunakawa; H. Ueno; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

A Phase I study to assess the safety, to

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

Phase I open-label study of cediranib, a

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

✍ Tanja Trarbach, Beate Schultheis, Thomas C. Gauler, Vesile Schneider, Dirk Strum 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 379 KB